Gloria Maguadog
Addiction Medicine · Houston, TXNPI 1316105232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 736 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Among addiction medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 736 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- Indivior Inc.$888
- Johnson & Johnson$846
- plus $5K from 19 others
What the payments were for
- Food & beverage$13,40497%
- Education$3603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 97 | $2,040 |
| Neurocrine Biosciences, Inc. | 75 | $1,917 |
| Otsuka America Pharmaceutical, Inc. | 94 | $1,787 |
| Alkermes, Inc. | 74 | $1,459 |
| Indivior Inc. | 57 | $888 |
| Johnson & Johnson | 57 | $846 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $764 |
| Corium, LLC | 55 | $706 |
| Vanda Pharmaceuticals Inc. | 36 | $653 |
| E.r. Squibb & Sons, L.L.C. | 31 | $566 |
| Lundbeck LLC | 26 | $480 |
| Axsome Therapeutics, Inc. | 17 | $398 |
| Ironshore Pharmaceuticals Inc. | 17 | $265 |
| Tris Pharma Inc | 10 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $199 |
| Supernus Pharmaceuticals, Inc. | 7 | $133 |
| Merck | 6 | $110 |
| Noven Therapeutics, LLC | 4 | $80 |
| Almatica Pharma LLC | 4 | $76 |
| Harmony Biosciences LLC | 2 | $57 |
| Collegium Pharmaceutical, Inc. | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Neuronetics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,763 in reported general payments places this provider in the 95th percentile of 42 addiction medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 106 | $330,029 |
| RexultiBrexpiprazole | 81 | $121,540 |
| LybalviOlanzapine/Samidorphan Malate | 57 | $96,775 |
| Abilify MaintenaAripiprazole | 28 | $77,734 |
| AustedoDeutetrabenazine | 11 | $60,398 |
| PerserisRisperidone | 18 | $51,326 |
| Adderall XrDextroamphetamine/Amphetamine | 117 | $45,457 |
| Lurasidone Hcl | 89 | $28,430 |
| FanaptIloperidone | 15 | $27,813 |
| TrintellixVortioxetine Hydrobromide | 39 | $18,770 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 211 | $16,695 |
| Aripiprazole | 178 | $13,446 |
| Asenapine Maleate | 34 | $11,367 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $10,143 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $846 | $330,029106 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,787 | $199,274109 claims |
| Alkermes, Inc.Lybalvi | $1,459 | $96,77557 claims |
| Indivior Inc.Perseris, Suboxone | $888 | $61,46931 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,040 | $60,39811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $199 | $28,02062 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $653 | $27,81315 claims |
| MerckBelsomra | $110 | $7,91618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 42 addiction medicine providers in Texas.
Other addiction medicine in Houston
- Thomas KostenHouston$85K
- James LaiHouston$6K
- Michael SprintzHouston$2K
- Robert LeathHouston$1K
- Hiroko FuroHouston$620
- Michael WeaverHouston$493
- John MohneyHouston$298
- Kamal ShahHouston$199
- Jason PowersHouston$23
- Jose LeyvaHouston$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.